Every 10-Q that Remsleep Holding (RMSL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RMSL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RMSL filings page.
REMSleep Holdings, Inc. reported no revenue for the six months ended June 30, 2026 and a net loss of $393,410, reflecting ongoing operating and financing costs without offsetting sales. Total assets were $153,863, against total liabilities of $434,791, resulting in negative shareholders’ equity of $(280,928) and an accumulated deficit of $(18,684,466).
Operating activities used $418,377 of cash, which was partially funded by $203,863 of cash from financing activities, including $35,000 in new convertible notes and common stock issuances. The company issued 80,419,997 new common shares, bringing total common shares outstanding to 1,739,610,123 as of June 30, 2026.
Management discloses substantial doubt about the company’s ability to continue as a going concern due to recurring losses, negative cash flows and reliance on external financing. Disclosure controls and procedures were concluded to be not effective because of a lack of segregation of duties.
REMSleep Holdings, Inc. reports first-quarter 2026 results showing no revenue and a larger net loss of $289,924, compared with $85,488 a year earlier. Total assets were $223,512 against liabilities of $346,063, resulting in negative equity of $122,551.
The company had cash of $87,953 and used $176,561 of cash in operating activities, funded in part by $50,000 of new convertible debt. An accumulated deficit of $18.58 million and recurring losses led management to state there is substantial doubt about its ability to continue as a going concern.
During the quarter, 35,419,997 common shares were issued on conversion of debt, bringing common shares outstanding to 1,694,610,123 as of June 9, 2026. Subsequent events include a change in control, a new management team, relocation of operations to Florida, and approval of 45,000,000 restricted shares as equity compensation and settlement.
REMSleep Holdings (RMSL) reported Q3 2025 results showing a much larger loss while beginning sales of its DeltaWave CPAP interface. Revenue for the quarter was $7,454, down from $37,260 a year earlier, and the quarterly net loss widened to $2,312,146. For the first nine months of 2025, revenue was $12,278 versus $122,735 in 2024, with a net loss of $2,685,406 and an accumulated deficit of $17,956,162.
Results were heavily affected by a $2,160,000 non-cash compensation expense from issuing Series C preferred stock to the CEO and a related party. The company relies on multiple convertible promissory notes from 1800 Diagonal, which generated significant interest expense and share issuances totaling 73,214,713 shares in the period. At September 30, 2025, cash was $343,948 and net cash used in operating activities was $373,395. Management states there is substantial doubt about the company’s ability to continue as a going concern. Common shares outstanding were 1,617,658,094 as of November 18, 2025.